A. Pelusio

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Aaron Fenster, James Burke, Andrew R. Haas, 2011, Nature.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Joon-Oh Park, R. Patt, S. Park, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

C. Rooney, D. Kirn, C. Breitbach, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

J. Burke, R. Patt, R. Lencioni, 2019, Oncoimmunology.

PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.

P. Galle, K. Brown, M. Borad, 2016 .